Quick Answer: In 2026, Skyrizi's cash list price is approximately $20,200 to $24,000 per single 150 mg dose, or roughly $85,000 to $105,000 per year for the standard psoriasis maintenance schedule of one dose every 12 weeks. Medicare covers self-injected Skyrizi under Part D, and your out-of-pocket spending across all Part D drugs is capped at $2,100 for 2026. Skyrizi is not one of the drugs selected for Inflation Reduction Act price negotiation in 2026 or 2027, so there is no negotiated Maximum Fair Price. AbbVie's Skyrizi Complete copay card can lower commercial-insurance costs to $0 per dose (up to $14,000 per year), but federal law bars its use with Medicare, Medicaid, TRICARE, or VA coverage. The myAbbVie Assist patient assistance program can supply Skyrizi free to eligible uninsured patients earning up to 600% of the federal poverty level, and to some Medicare Part D patients who do not qualify for Extra Help.
Skyrizi is the brand name for risankizumab-rzaa, an interleukin-23 (IL-23) inhibitor manufactured by AbbVie. The FDA approved Skyrizi in April 2019 for moderate to severe plaque psoriasis, then expanded approval to active psoriatic arthritis, moderately to severely active Crohn's disease, ulcerative colitis, and pediatric plaque psoriasis and psoriatic arthritis in patients age 6 and older. Skyrizi works by blocking the p19 subunit of IL-23, a protein that drives inflammation in these autoimmune conditions.
AbbVie's wholesale acquisition cost for Skyrizi reached approximately $23,838.42 per 150 mg dose as of January 2026. Dosing depends on the condition: patients with plaque psoriasis and psoriatic arthritis typically get 150 mg subcutaneously at week 0, week 4, and then every 12 weeks. Patients with Crohn's disease or ulcerative colitis start with three intravenous induction infusions (600 mg each) at weeks 0, 4, and 8, then switch to subcutaneous maintenance doses of 180 mg or 360 mg every 8 weeks starting at week 12. Because the drug is billed per dose rather than per month, what you actually owe depends heavily on your insurance type, your indication, and whether AbbVie's savings programs apply. Patients also managing other biologics should compare Humira's biosimilar switch options or Stelara's IRA-negotiated 2026 price, since payers often require step therapy through those drugs before approving Skyrizi.
Skyrizi became AbbVie's top revenue product after Humira lost patent exclusivity and faced biosimilar competition starting in 2023. Unlike Humira, no biosimilar or generic version of Skyrizi exists as of 2026, and none is expected before AbbVie's core composition patent expires around 2032. The Centers for Medicare & Medicaid Services has not selected Skyrizi for Inflation Reduction Act price negotiation in either the first round (effective 2026) or the second round (effective 2027), so there is no government-negotiated Maximum Fair Price for this drug. That could change in future negotiation cycles given Skyrizi's rising Part D spending.
What Skyrizi Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same skyrizi can cost many times more at a hospital than at your local pharmacy:
2026 Skyrizi Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Medicare ASP rate (Part B, IV induction) | $14.53/mg (J2327); ~$8,718 for a 600 mg infusion | You pay 20% coinsurance after the $283 Part B deductible for 2026 |
| Specialty pharmacy counter (retail, cash) | $20,200 - $24,000/dose | List price for a single 150 mg subcutaneous pen or syringe without insurance |
| Medicare Part D (2026) | Formulary-tier copay, capped at $2,100/year total | Usually placed on the highest specialty tier; prior authorization required |
| Commercial insurance with Skyrizi Complete card | As low as $0/dose (up to $14,000/year) | Not available with Medicare, Medicaid, TRICARE, or VA coverage |
| Medicaid | $1 - $4/prescription, with PA | Covered for FDA-approved indications; step therapy varies by state |
Retail figures reflect 2026 GoodRx and AbbVie wholesale acquisition cost data. Part D copays depend on your plan's formulary tier and where you are in the benefit year.
Source: CMS Medicare Part B ASP Pricing File (J2327), CMS Part D 2026 benefit design, AbbVie Skyrizi Complete, GoodRx
Why Hospitals Charge So Much
Crohn's disease and ulcerative colitis patients receive their first three Skyrizi doses as 600 mg intravenous infusions, usually administered at a hospital outpatient infusion center or an independent infusion clinic. Hospital-based infusion centers routinely charge facility fees, infusion administration fees, and nursing time on top of the drug's own acquisition cost, which can push a single infusion bill well past $110,000 to $180,000 once markups are applied. The same 600 mg dose given at a lower-cost independent infusion center typically runs substantially less because it avoids the hospital facility fee.
Maintenance doses for plaque psoriasis and psoriatic arthritis are almost always self-injected at home with the Skyrizi Pen or prefilled syringe, so they rarely generate a hospital bill. When a Skyrizi charge does appear on an inpatient itemized bill, ask for the National Drug Code (NDC) and the line-item cost. The 2026 wholesale acquisition cost is about $158.92 per mg, so a 150 mg dose should price near $23,838 before any facility markup. Charges significantly above that figure for the drug line item, separate from infusion or administration fees, are common dispute targets.
HCPCS J-Codes: What Appears on Your Bill
Skyrizi's intravenous induction doses for Crohn's disease and ulcerative colitis are billed under Medicare Part B using a single HCPCS Level II J-code. Self-injected maintenance doses are billed under Part D instead and do not use a J-code.
HCPCS J-codes for Skyrizi| Code | Description | What to look for |
|---|
| J2327 | Injection, risankizumab-rzaa (Skyrizi), intravenous, 1 mg | Confirm the billed mg count matches your 600 mg induction dose (600 units of J2327) and that you were not also billed a separate self-injection code for the same visit. |
J2327 applies only to the IV induction formulation used for Crohn's disease and ulcerative colitis. Subcutaneous maintenance doses for all indications are dispensed through a specialty pharmacy and billed under your Part D or commercial pharmacy benefit, not Part B.
Source: CMS HCPCS Level II code set, effective January 1, 2023
Patient Assistance Programs
AbbVie, the manufacturer of Skyrizi, runs two primary assistance tracks: a copay savings card for commercially-insured patients and a free-drug patient assistance program for uninsured and underinsured patients. If you have no insurance, the myAbbVie Assist patient assistance program is generally the largest cost reduction available, often bringing your total Skyrizi cost to $0.
Patient assistance programs for Skyrizi| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Skyrizi Complete Savings Card | As low as $0 per dose for commercially-insured patients, up to $14,000 per calendar year | skyrizi.com/skyrizi-complete |
| myAbbVie Assist Patient Assistance Program | Free Skyrizi for uninsured patients at or below 600% of the federal poverty level; also available to some Medicare Part D patients without Extra Help | abbvie.com/myabbvieassist |
| Patient Access Network (PAN) Foundation IBD Fund | Copay and premium assistance grants for Medicare patients with Crohn's disease or ulcerative colitis, subject to fund availability | panfoundation.org |
| NeedyMeds Drug Discount Card | Variable discount accepted at most US pharmacies, not specific to Skyrizi | needymeds.org |
Manufacturer copay cards and coupons like Skyrizi Complete are blocked by federal anti-kickback law (42 U.S.C. § 1320a-7b) for anyone with Medicare, Medicaid, TRICARE, or VA coverage. A manufacturer coupon lowers your copay but does not lower what your insurer is billed, which is why federal law treats it as a kickback risk when a government program pays the claim. If you have government insurance, apply for myAbbVie Assist or the PAN Foundation grant instead. Medicaid beneficiaries are not eligible for myAbbVie Assist because Medicaid already covers the drug with a small state copay.
Source: AbbVie patient support pages, PAN Foundation, NeedyMeds.org
Medicare Part D
Skyrizi's self-injected doses are a Medicare Part D drug. For 2026, your total annual out-of-pocket cost across all Part D drugs combined is capped at $2,100 under the Inflation Reduction Act. Most Part D plans place Skyrizi on their highest specialty tier, which typically means 25% to 33% coinsurance until you reach the annual cap, after which you pay $0 for the rest of the calendar year on covered drugs, including Skyrizi.
Prior authorization and step therapy are standard for Skyrizi under Medicare Part D and most commercial plans. Many formularies require documented failure of, or intolerance to, a lower-cost biologic such as adalimumab (Humira and its biosimilars) or ustekinumab (Stelara and its biosimilars) before approving Skyrizi. Ask your prescriber's office to submit the prior authorization with your full treatment history to avoid a delayed or denied first fill.
The Medicare Prescription Payment Plan, available since 2025, lets Part D enrollees spread their out-of-pocket Skyrizi costs evenly across the calendar year instead of paying a large coinsurance bill in the month of the first fill. Ask your Part D plan to enroll you if a single Skyrizi dose would otherwise create a large upfront bill.
Common Skyrizi Billing Errors
If you received a Skyrizi bill above $2,100 for the year under Medicare Part D, or an infusion bill above $180,000, check for these issues before paying:
- Prior authorization not submitted, or step therapy documentation missing, causing a denial and a full cash-price bill for a dose that should have been covered.
- IV induction infusion billed with a self-injection administration code, or vice versa. The route of administration changes both the HCPCS code and which part of Medicare pays.
- Skyrizi Complete copay card not applied at the specialty pharmacy counter even though you have qualifying commercial insurance. Ask the pharmacy to rerun the claim with the savings card BIN/PCN before paying cash.
- Coinsurance charged at the full formulary-tier rate after you already crossed the $2,100 Part D out-of-pocket cap for the year.
- Copay accumulator or copay maximizer programs that prevent Skyrizi Complete savings from counting toward your deductible, leaving you owing the full deductible later in the year.
- Hospital infusion center billing a facility fee and a separate drug-handling fee on top of the J2327 drug charge for a routine outpatient induction dose.
Frequently Asked Questions
Is there a generic or biosimilar for Skyrizi?
No. As of 2026, there is no FDA-approved generic or biosimilar version of Skyrizi (risankizumab-rzaa). AbbVie's core composition patent is not expected to expire until approximately 2032, and while at least one candidate biosimilar is in early clinical trials, none has reached FDA approval. Patients looking for a lower-cost option in the same drug class can ask their prescriber about biosimilar ustekinumab, a lower-cost version of Stelara.
How do I apply for the AbbVie myAbbVie Assist patient assistance program for Skyrizi?
Visit abbvie.com/myabbvieassist or call 1-800-222-6885 to start the application. You and your prescriber both complete sections of the form, and you submit proof of income, proof of US residency, and proof of your insurance status (or lack of insurance). Uninsured patients earning up to 600% of the federal poverty level generally qualify for free Skyrizi. Processing typically takes 7 to 14 business days, and approved patients receive up to 12 months of medication before needing to reapply.
Can I use the Skyrizi Complete savings card with Medicare?
No. Federal anti-kickback law prohibits manufacturer copay savings cards, including Skyrizi Complete, from being used by anyone with Medicare, Medicaid, TRICARE, or VA coverage. Skyrizi Complete is reserved for commercially-insured patients and can lower your cost to $0 per dose, up to $14,000 per year. If you have Medicare, apply for the myAbbVie Assist patient assistance program or a foundation grant instead.
What if my insurance denies coverage for Skyrizi?
First, request the written denial notice, which states the specific reason. File a formal internal appeal within your plan's deadline (typically 60 to 180 days) and ask your prescriber to submit clinical documentation showing prior biologic failures or contraindications. If your plan requires step therapy through Humira or Stelara first, your prescriber can request a step-therapy override. If the appeal still fails, apply for the myAbbVie Assist program while you pursue an external review through your state Department of Insurance or Medicare's independent review entity.
Does the IRA negotiated price apply to Skyrizi?
No. Skyrizi was not selected for Medicare drug price negotiation under the Inflation Reduction Act in the first round (effective 2026) or the second round (effective 2027). There is no negotiated Maximum Fair Price for Skyrizi as of 2026. Medicare Part D enrollees instead rely on the general $2,100 annual out-of-pocket cap that applies to all Part D drugs combined in 2026, regardless of negotiation status.
What does Skyrizi cost without insurance at the pharmacy counter in 2026?
The 2026 cash price for a single 150 mg Skyrizi dose ranges from about $20,200 to $24,000 depending on the specialty pharmacy, with AbbVie's wholesale acquisition cost near $23,838. For plaque psoriasis, dosed roughly every 12 weeks, that adds up to about $85,000 to $105,000 per year without insurance or assistance. Uninsured patients should apply for the myAbbVie Assist program before paying cash.
Do I qualify for the myAbbVie Assist patient assistance program?
You likely qualify if you are uninsured, a US resident, have a valid Skyrizi prescription, and your household income is at or below 600% of the federal poverty level (for example, about $198,000 for a household of 4 in 2026). Some Medicare Part D patients without the Extra Help Low-Income Subsidy can also qualify, but they must first apply for or be denied Extra Help. Medicaid beneficiaries do not qualify because Medicaid already covers Skyrizi.
How is Skyrizi dosing different for psoriasis versus Crohn's disease or ulcerative colitis?
For plaque psoriasis and psoriatic arthritis, Skyrizi is given as a 150 mg subcutaneous injection at week 0, week 4, and then every 12 weeks, all self-administered at home. For Crohn's disease and ulcerative colitis, patients first receive three 600 mg intravenous induction infusions at weeks 0, 4, and 8 in a clinical setting, then switch to subcutaneous maintenance doses of 180 mg or 360 mg every 8 weeks. The IV induction phase is billed under Medicare Part B using J-code J2327, while all subcutaneous maintenance dosing is billed under Part D or commercial pharmacy benefits.
